Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 5/20 | 0.59 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483223 | 0.90 | KDM4E (0.65) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29393776 | 0.90 | KDM4E (0.65) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL541514 | 0.89 | KDM4E (0.64) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28424222 | 0.89 | KDM4E (0.64) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL541515 | 0.89 | KDM4E (0.64) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10330779 | 0.88 | TOP2A (0.56) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30353209 | 0.88 | KCNH2 (0.65) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28386544 | 0.88 | KCNH2 (0.65) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5704390 | 0.88 | KDM4E (0.63) | KCNH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5455055 | 0.88 | KDM4E (0.63) | KCNH2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2009012-B1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | RES FOUND ITSUU LAB (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7732612-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | BCL6B, BCL6, BLVRB | KCNH2 4184/4885KDM4E 3691/4885ALDH1A1 4730/4885 |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | NQO2, QRFPR, NQO1 | KCNH2 519/4885KDM4E 2073/4885ALDH1A1 1307/4885 |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | PELP1, MLN, SND1 | KCNH2 4321/4885KDM4E 3997/4885ALDH1A1 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.